Profile data is unavailable for this security.
About the company
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company’s products include APIs and Impurities. The Company offers reference standards and impurities for various APIs under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for quick and reliable supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories. Its products include Clarithromycin, Clarithromycin Coated Granules, Ezetimibe, Pazopanib HCl, Ranolazine, Aripiprazole, Letrozole, and Imatinib Mesylate, others.
- Revenue in INR (TTM)7.26bn
- Net income in INR3.73bn
- Incorporated1995
- Employees47.00
- LocationIND Swift Laboratories LtdSCO 850NAC, Shivalik Enclave,, ManimajraCHANDIGARH 160101IndiaIND
- Phone+91 1 725061850
- Fax+91 1 722730504
- Websitehttps://www.indswiftlabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Ltd | 1.58bn | 164.61m | 4.92bn | 168.00 | 29.78 | 2.60 | 28.38 | 3.12 | 10.28 | 10.28 | 98.44 | 117.72 | 0.6347 | 26.77 | 2.29 | 9,377,369.00 | 5.70 | 3.38 | 7.93 | 4.76 | 34.75 | 35.33 | 8.98 | 6.17 | 2.01 | 2.81 | 0.1467 | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| ZIM Laboratories Ltd | 3.88bn | 161.50m | 5.02bn | 556.00 | 31.14 | 2.07 | 14.80 | 1.29 | 3.31 | 3.31 | 79.19 | 49.82 | 0.9788 | 2.67 | 5.18 | 6,980,632.00 | 4.07 | 3.88 | 5.70 | 6.54 | 53.95 | 47.45 | 4.16 | 3.97 | 0.9475 | 2.77 | 0.3004 | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Lyka Labs Ltd | 1.32bn | 33.80m | 5.05bn | 423.00 | 153.48 | 5.11 | 40.80 | 3.84 | 0.9226 | 0.9226 | 37.94 | 27.71 | 0.8222 | 6.01 | 3.92 | 3,111,116.00 | 1.95 | -5.48 | 2.50 | -8.30 | 59.65 | 60.82 | 2.38 | -9.16 | 1.23 | 2.34 | 0.2627 | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| Accent Microcell Ltd | 2.62bn | 325.33m | 5.06bn | 174.00 | 12.14 | 2.84 | 14.10 | 1.93 | 19.80 | 19.80 | 141.04 | 84.68 | 1.65 | 4.64 | 6.67 | 15,070,950.00 | 20.43 | -- | 24.77 | -- | 32.30 | -- | 12.41 | -- | 4.81 | -- | 0.0114 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Medicamen Biotech Ltd | 1.82bn | 64.80m | 5.49bn | 378.00 | 60.80 | 2.53 | 39.76 | 3.02 | 7.10 | 7.10 | 165.42 | 170.67 | 0.6199 | 1.67 | 2.76 | 4,804,595.00 | 1.99 | 5.89 | 2.76 | 8.45 | 46.53 | 36.54 | 3.22 | 9.58 | 1.41 | 2.67 | 0.0854 | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| IND Swift Laboratories Ltd | 7.26bn | 3.73bn | 6.07bn | 47.00 | 1.62 | 0.600 | 1.52 | 0.836 | 63.24 | 63.24 | 123.25 | 171.20 | 0.486 | 1.73 | 2.54 | 154,462,200.00 | 25.01 | 5.00 | 29.88 | 6.13 | 46.23 | 41.12 | 51.47 | 8.52 | 3.51 | 7.87 | 0.016 | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Sakar Healthcare Ltd | 1.64bn | 124.03m | 6.20bn | 325.00 | 50.15 | 2.01 | 19.43 | 3.77 | 5.68 | 5.68 | 75.48 | 141.51 | 0.4312 | 3.22 | 7.45 | 5,052,619.00 | 3.25 | 5.26 | 3.85 | 6.28 | 44.83 | 43.47 | 7.55 | 10.12 | 0.6515 | 3.28 | 0.2374 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Wanbury Ltd | 5.77bn | 529.62m | 6.99bn | 1.49k | 13.57 | 18.05 | 10.57 | 1.21 | 15.73 | 15.73 | 173.33 | 11.83 | 1.55 | 7.95 | 6.17 | 3,871,231.00 | 14.26 | 11.63 | 39.18 | -- | 49.84 | 42.46 | 9.18 | 7.62 | 0.6908 | 1.71 | 0.8235 | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Albert David Ltd | 3.65bn | 685.47m | 7.28bn | 1.50k | 10.61 | 1.76 | 9.63 | 1.99 | 120.12 | 120.12 | 639.84 | 724.06 | 0.7377 | 2.83 | 10.89 | 2,439,081.00 | 13.85 | 10.00 | 17.15 | 13.15 | 66.12 | 59.85 | 18.77 | 11.87 | 3.65 | 53.46 | 0.0085 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Nectar Lifesciences Ltd | 16.79bn | 107.27m | 7.69bn | 1.69k | 71.93 | 0.7133 | 10.71 | 0.4578 | 0.4766 | 0.4766 | 73.70 | 48.06 | 0.7764 | 1.67 | 4.94 | 9,960,952.00 | 0.496 | -0.2956 | 0.8778 | -0.541 | 30.41 | 16.49 | 0.6388 | -0.4053 | 0.5576 | 1.25 | 0.3686 | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
